🇺🇸 ABT in United States

320 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 320

Most-reported reactions

1. Febrile Neutropenia — 78 reports (24.38%)
2. Anaemia — 41 reports (12.81%)
3. Nausea — 37 reports (11.56%)
4. Dehydration — 28 reports (8.75%)
5. Vomiting — 25 reports (7.81%)
6. White Blood Cell Count Decreased — 25 reports (7.81%)
7. Pneumonia — 24 reports (7.5%)
8. Neutrophil Count Decreased — 22 reports (6.88%)
9. Fatigue — 21 reports (6.56%)
10. Dyspnoea — 19 reports (5.94%)

Source database →

Frequently asked questions

Is ABT approved in United States?

ABT does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ABT in United States?

Shanghai Public Health Clinical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.